Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation …
M Grymonprez, K Vanspranghe… - British Journal of …, 2022 - Wiley Online Library
Aims P‐glycoprotein (P‐gp) and CYP3A4‐interacting drugs influence plasma levels of non‐
vitamin K antagonist oral anticoagulants (NOACs). However, the clinical relevance is …
vitamin K antagonist oral anticoagulants (NOACs). However, the clinical relevance is …
Risk of bleeding with the concurrent use of amiodarone and DOACs: A systematic review and meta-analysis
F Michael, T Quevilllon, S Maisonneuve… - European Heart …, 2024 - academic.oup.com
Abstract Background and Aims Amiodarone is frequently prescribed alongside direct oral
anticoagulants (DOACs) in atrial fibrillation (AF). There are concerns regarding drug-drug …
anticoagulants (DOACs) in atrial fibrillation (AF). There are concerns regarding drug-drug …
[HTML][HTML] Risk of Major bleeding in patients with atrial fibrillation taking dronedarone in combination with a direct acting oral anticoagulant (from a US Claims database)
SK Gandhi, JA Reiffel, R Boiron, M Wieloch - The American Journal of …, 2021 - Elsevier
Dronedarone may increase exposure and the risk of major bleeding when prescribed with a
direct oral anticoagulant (DOAC). This retrospective cohort study examined the risk of the …
direct oral anticoagulant (DOAC). This retrospective cohort study examined the risk of the …
Combination of rivaroxaban and amiodarone increases bleeding in patients with atrial fibrillation
Z Wang, X Li, Y Zou, X Li, Q Lv - Annals of Pharmacotherapy, 2024 - journals.sagepub.com
Background: Rivaroxaban and amiodarone are commonly used for treating patients with
atrial fibrillation. Drug-drug interactions between rivaroxaban and amiodarone may increase …
atrial fibrillation. Drug-drug interactions between rivaroxaban and amiodarone may increase …
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants
Aims Limited data compared antiarrhythmic drugs (AADs) with concomitant non-vitamin K
antagonist oral anticoagulants in atrial fibrillation patients, hence the aim of the study …
antagonist oral anticoagulants in atrial fibrillation patients, hence the aim of the study …
Bleeding associated with antiarrhythmic drugs in patients with atrial fibrillation using direct oral anticoagulants: A nationwide population cohort study
VCC Wu, CL Wang, YC Huang, HT Tu… - Journal of the …, 2024 - ahajournals.org
Background This study investigated drug–drug interactions in patients with atrial fibrillation
taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug. Methods and …
taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug. Methods and …
Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: Application to …
JWH Leow, XJ Ang, ECY Chan - British Journal of Clinical …, 2023 - Wiley Online Library
Aims Despite potential enzyme‐and transporter‐mediated drug–drug interactions (DDIs)
between dronedarone and rivaroxaban in atrial fibrillation (AF) patients, pharmacokinetic …
between dronedarone and rivaroxaban in atrial fibrillation (AF) patients, pharmacokinetic …
Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation
Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial,
demonstrating safety in the Asian population. It remains unclear whether treatment with …
demonstrating safety in the Asian population. It remains unclear whether treatment with …
[HTML][HTML] Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
H Ding, Z Wang, J Wang, Y Yao, C Zhang, H Lin… - Pharmaceutics, 2024 - mdpi.com
This study aimed to investigate the impact of the drug–drug interaction between rivaroxaban
and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation …
and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation …
Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation
The current treatment paradigm for atrial fibrillation (AF) prioritizes rate control over rhythm
control; however, rhythm control has shown benefits over other AF strategies. This study …
control; however, rhythm control has shown benefits over other AF strategies. This study …